AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2018

Jul 31, 2018

34238_dirs_2018-07-31_0d0813cd-7122-4026-a850-49f3e0d155d3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-07-26

Reporting Person: HESTERBERG LYNDAL K. (Sr VP, Research & Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-26	Common stock, no par value	P	874	—	Acquired	874	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-26	Common stock purchase warrants	$3.00	P	874	Acquired	2024-02-01	Common stock (874)	Direct

Footnotes

F1: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86.